Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Rare codons capacitate Kras-driven de novo tumorigenesis
Nicole L.K. Pershing, … , David M. MacAlpine, Christopher M. Counter
Nicole L.K. Pershing, … , David M. MacAlpine, Christopher M. Counter
Published December 1, 2014
Citation Information: J Clin Invest. 2015;125(1):222-233. https://doi.org/10.1172/JCI77627.
View: Text | PDF
Research Article Oncology

Rare codons capacitate Kras-driven de novo tumorigenesis

  • Text
  • PDF
Abstract

The KRAS gene is commonly mutated in human cancers, rendering the encoded small GTPase constitutively active and oncogenic. This gene has the unusual feature of being enriched for rare codons, which limit protein expression. Here, to determine the effect of the rare codon bias of the KRAS gene on de novo tumorigenesis, we introduced synonymous mutations that converted rare codons into common codons in exon 3 of the Kras gene in mice. Compared with control animals, mice with at least 1 copy of this Krasex3op allele had fewer tumors following carcinogen exposure, and this allele was mutated less often, with weaker oncogenic mutations in these tumors. This reduction in tumorigenesis was attributable to higher expression of the Krasex3op allele, which induced growth arrest when oncogenic and exhibited tumor-suppressive activity when not mutated. Together, our data indicate that the inherent rare codon bias of KRAS plays an integral role in tumorigenesis.

Authors

Nicole L.K. Pershing, Benjamin L. Lampson, Jason A. Belsky, Erin Kaltenbrun, David M. MacAlpine, Christopher M. Counter

×

Figure 2

Krasex3op/nat mice are resistant to urethane.

Options: View larger image (or click on image) Download as PowerPoint
Krasex3op/nat mice are resistant to urethane.
(A) Strategy to generate K...
(A) Strategy to generate Krasex3op/nat CMV-Cre and Krasnat/nat CMV-Cre F1 mixed-background littermates for urethane carcinogenesis. (B–D) Reduction of tumor burden (mean ± SEM) in Krasex3op/nat CMV-Cre versus Krasnat/nat CMV-Cre mice (B) 11–12 months (n ≥8, **P < 0.01) or (C) 9 months (n ≥ 11, *P < 0.05) after urethane administration and (D) Krasex3op/nat CMV-Cre versus Krasnat/nat CMV-Cre mice generated from a second founder line 9 months after urethane administration (n = 9, ****P < 0.0001). P values were calculated by an unpaired, 2-tailed t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts